English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The objectives of this article were to identify the potential Romanian psoriatic arthritis patients (PsA) subpopulation in need for new therapeutic principles, currently unavailable in our country. Data were retrieved electronically from the Romanian Registry for Rheumatic Diseases (RRBR) database between January 1 and December 31 2017. In order to define remission and low disease activity, patients were assessed with the Disease Activity in Psoriatic Arthritis (DAPSA) and Simplified Disease Activity Index scores. Of the 804 PsA patients enrolled in RRBR in 2017, 721 (89.7%) patients were treated with biologics for more than 6 months. Of these, 86 patients (11.9%) were in moderate and high disease activity according to DAPSA and 196 patients (27.2%) according to SDAI, respectively. Compared to patients in DAPSA remission or low disease activity, these patients had a higher toll of inflammation and a higher prevalence of sacroiliitis. Up to 30% of Romanian PsA patients registered in RRBR would be candidates for new and locally unavailable biologic and synthetic disease-modifying anti-rheumatic drugs, such as abatacept, apremilast, certolizumab, ixekizumab, tofacitinib and ustekinumab.

UNMET THERAPEUTIC NEEDS IN PSORIATIC ARTHRITIS: DATA FROM THE ROMANIAN REGISTRY OF RHEUMATIC DISEASES – NEW THERAPIES AND TARGETS